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The once-settled roles of all dietary fatty acid classes vis-à-vis coronary heart disease (CHD) seem to be under fire these days. For decades it had been received wisdom that "saturated fats are bad," and that margarines should replace butter to reduce risk for heart attacks. But a recent Time magazine cover that screamed, "EAT BUTTER" illustrates this changing perspective 1 .
Olive oil, the poster child of the "Mediterranean Diet" and a rich source of oleic acid, has long been nearly worshiped as cardioprotective, but recent meta-analyses 2 and animal feeding studies 3 are challenging this view. Similarly, the marine-derived omega-3 fatty acids, which have historically found a place among the "healthiest" of all dietary fats have fallen on hard times based on the null findings in several recent randomized trials 4 , and now linoleic acid (LA), the principal vegetable-oil derived omega-6 fatty acid -once taken as a medicine by the tablespoon to lower cholesterol -is now being accused of causing, not preventing heart disease 5 . The only class that seems to be holding its own is the industrially-produced trans fats which, although clearly promoting CHD, are also slowly disappearing from the American diet 6 . Understandably, the American public is becoming jaded when it comes to official proclamations of what constitutes a "healthy fat."
In this context, careful examination of the dietary patterns of large numbers of individuals followed for many years as they relate to CVD can help bring perspective. Such is the contribution of Farvid et al. in this issue of Circulation 7 . These investigators performed the largest systematic review and meta-analysis to date examining the relations between omega-6 fatty acid (essentially LA) intake and CHD morbidity and mortality. Utilizing data from both cohort studies involving about 290,000 individuals among whom occurred nearly 11,000 CHD events and about 4500 CHD deaths. Intakes of LA were estimated by a variety of dietary principal vegetable-oil derived omega-6 fatty acid -once taken as a medicine by y the he e t tab ab able le lesp sp spoo oon o lower cholesterol -is now being accused of causing, not preventing heart disease 5 . The only cl las as ss s s th th th t at at s s see ee e m ms ms t t to o o be b holding its own is the indus us ustr ri ially-produced d d tran an ns s s f f fat a s which, although cl lea a arl r y promot otin in ng CH H HD, D, , a a ar re re a al ls lso o sl sl s o ow owly ly disa ap appea ar rin ng f fr fro om om th he he A A Am me meri ri ic c can n n di di iet et et 6 6 6 . . Un Un Unde de ders rs sta a and n nda ab a l ly ly, questionnaires, and follow-up ranged from 5 to 30 years. Comparing the highest to the lowest intake groups, risk for CHD events was lower by 14% and for CHD death by 17%, both statistically significant. The effects on total mortality would have been of interest as well, but such data were not available. The authors note that several studies have sought effects of dietary LA on cancer outcomes but have found none.
The fact that these relations were observed using such blunt instruments as dietary questionnaires suggests the findings are robust. The observation that replacing either saturated fats or carbohydrates with vegetable oils produced essentially the same CHD benefit suggests that it is not the nutrient being replaced by LA that affords the benefit but the LA itself. Finally, since the LA effect was independent of the intake of alpha-linolenic acid (ALA, the plant omega-3 fatty acid found primarily in soybean oil, which provides about 6% of total fatty acids as ALA and 54% as LA), the benefit observed cannot be attributed to consumption of the ALA alone as some have hypothesized 5 .
These findings contrast with of a recent paper by Chowdhury et al. 2 who reported, based on the results of 8 prospective cohort studies, that there was no association [hazard ratio (HR) of 0.98, 95% confidence interval (CI) 0.94 to 1.02] between omega-6 fatty acid intake (not LA, per se) and "coronary disease" (defined as fatal or nonfatal myocardial infarction, coronary heart disease, coronary insufficiency, coronary death, angina, and/or angiographic coronary stenosis).
Some of the possible reasons for this discrepancy are discussed in Farvid et al.
Omega-6 are Proinflammatory?
As noted earlier, some investigators have proposed that LA intakes in America are excessive 8 , and far from reducing risk for inflammatory diseases like CHD, may actually be increasing risk 5 . This perspective builds upon the following logic: since 1) LA is a precursor for arachidonic ince the LA effect was independent of the intake of alpha-linolenic acid (ALA, t th the e e pl pl lan an ant t t om om omeg ega 3 fatty acid found primarily in soybean oil, which provides about 6% of total fatty acids as ALA an nd d d 54 54 54% % % as as as L L LA) ), , th th the e benefit observed cannot be e e a at a t tr ributed to con nsu su s mp mpti ti tio on on of the ALA alone as o om me me have hy ypo poth th t es esiz iz ized ed d 5 5 5 . day increased their LA intake from 6.8% to 9.8% energy and raised plasma phospholipid levels by 2-4 percentage points
Another concern with increasing LA intake is that it will lower blood levels of the long al. 13 increased the LA intake from 3.8% to 10.5% of total energy in the diets of 22 men for 4
weeks. The high LA diet did lower plasma phospholipid EPA levels slightly (from 1% to 0.6%), but it raised DHA levels by the same amount (from 3% to 3.4%), leaving the sum of EPA+DHA (4%) unaffected. They also observed no effects on inflammatory markers or platelet aggregation with the high LA diet.
When Chowdhury, et al. 2 examined the relations between circulating fatty acids (i.e., biomarkers) and CHD, the omega-6 story became more complicated. There was no association between LA levels and disease, but contra the "omega-6-are-inflammatory" hypothesis, in 10 studies including some 23,000 individuals with over 3700 CHD events, higher levels of circulating AA -the presumed toxic mediator -were associated with lower risk for CHD events (HR, 0.83, 95% CI, 0.74 to 0.92).
Linoleic Acid Metabolites
As noted, the "LA is harmful" hypothesis depends heavily on the view that an LA metabolite, AA, is converted to potent pro-inflammatory signaling molecules. But AA is not the only LA metabolite with potential effects on CHD -LA itself can be converted to a wide variety of bioactive molecules. For example, nitrated LA (LNO 2 ) has been shown to have cardioprotective effects 14 . It can reduce cardiac ischemic injury by facilitating mitochondrial uncoupling, and it has been reported to inhibit platelet and neutrophil function, inhibit LPS-induced cytokine release from monocytes, improve insulin sensitivity, and relax pre-constricted aortic rings 14 . In addition, LNO 2 is a powerful ligand for PPAR- 15 , a nuclear transcription factor that controls cell differentiation as well as production of metabolic and anti-inflammatory signaling molecules. At physiologically-relevant levels LNO 2 rivals the effects of the thizoladinediones on PPAR- 15 .
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As As n n not ot oted ed e , , , th th the e e "L "LA A is is h h har ar rmf m ul ul l" hy hy hypo po poth the es esis is is d d dep ep e en en end ds ds h h hea a avi vi ily ly ly o on n n th th t e e vi vi view ew ew th ha hat t an an an L LA A A m m met t tab bo boli lit t te, , AA, is conve ert rt rted ed e t t to o o po po pote te ent t p p pro ro ro-i i inf nf nfla la amm mm mmat at tor or ory y y si si sign gn gnal al a in in ing g mo mo mole le lecu cu cule le les. s B B But ut ut A A AA A A is is i n n not ot ot t t the he he o only LA LNO 2 (as well as nitrated AA) can be esterified in cell membrane (and lipoprotein) phospholipids and cholesteryl esters. Hence the possibility of targeted delivery of these signaling molecules via lipoprotein receptors exists. Beyond that, LA can also be converted to a growing number of oxygenated metabolites (i.e., oxylipins) by cyclo-oxygenase, lipoxygenases, and/or cytochrome P-450 epoxygenases (Figure 1) . As just one example of the potential physiological effects of LA oxylipins, the anti-hypertensive effects of LA may be mediated, at least in part, by LA diols and triols which may inhibit tubular sodium reabsorption and thereby facilitate sodium excretion in salt-sensitive individuals 16 . LA can also be metabolized to DGLA (from which other bioactive lipids can be produced), and further to AA, which is the well-known precursor prostaglandin E2, thromboxane A2, and leukotriene B4, all "pro-inflammatory" mediators. But if one takes off the blinders and examines the entire AA metabolome, one finds a constellation of metabolites including a variety of prostaglandins, leukotrienes, ligands for endocannabinoid receptors, lipoxins, isoprostanes, nitrated AA, and epoxides, among others (Figure 1) . Some are "proinflammatory" but some are "anti-inflammatory" or promote the resolution of inflammatory insults. Often these effects have only been observed in certain cell/tissue types and under potentially non-physiological conditions, and their effects in normal physiology or those of other metabolites remain to be discovered. The net impact on human metabolism (and CHD risk) of this multitude of products will ultimately be determined by their interaction among themselves (and with their omega-3 fatty acid analogs), and is virtually impossible to predict. Hence, to label the entire class of omega-6 fatty acid metabolites as "proinflammatory" is painfully naïve.
Randomized Trials
Of course, the most direct way to test the hypothesis that higher LA intakes reduce risk for CHD is to perform a randomized controlled trial (RCT). This has been attempted many times, and nearly as Fi Figu gur r re 1 1 1) . ) ). S So om ome e e a a are "p "pro ro roin in infl fl f am am mma ma m to tor r ry" " " bu bu ut s so some me a are re e " "an an anti ti-i -i -nf nf nfla la lamm mm mmat ator or ory y y" or or r p p pr ro romo mo mot te e t t the he he r r res esol olut ut utio io on n n of of of i i inf nfl la lam mm mma a ato or ory y nsults. Often n t t the he h se se se e e eff ff ffec ec e ts s h h hav av a e e e on on o ly ly ly b b bee ee e n n n ob ob obse se serv rv ved ed ed i in n ce ce cert rt rtai ai ain n n ce ce cell l /t /t /tis is issu su sue e e ty ty type pe p s s s an an and d d un un under many meta-analyses have been employed to summarize their findings. Depending on which trials one includes, there is either a significant reduction in risk 17 , no effect 2 , or a trend towards increased risk 5 associated with higher omega-6 intakes. Space does not allow a consideration of the pros and cons of each approach. Suffice it to say that large-scale, multi-year intervention trials in which one major dietary component is (must be) substituted for another are both difficult to conduct and to interpret owing to the multiple variables involved. Hence, it has been argued that prospective cohort data should be given the same evidentiary weight as RCTs in nutrition because each has relevant strengths and weaknesses 18 . The report from Farvid et al. 7 makes an important contribution in this regard. Importantly, their data (shown in Figure 5 ) continue to support the recommendation of many health authorities for 5-10% of energy as LA 19, 20 .
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